MX2017008931A - Formulaciones farmaceuticas de xantina o derivados de xantina. - Google Patents

Formulaciones farmaceuticas de xantina o derivados de xantina.

Info

Publication number
MX2017008931A
MX2017008931A MX2017008931A MX2017008931A MX2017008931A MX 2017008931 A MX2017008931 A MX 2017008931A MX 2017008931 A MX2017008931 A MX 2017008931A MX 2017008931 A MX2017008931 A MX 2017008931A MX 2017008931 A MX2017008931 A MX 2017008931A
Authority
MX
Mexico
Prior art keywords
xanthine
pharmaceutical formulations
derivatives
compositions
methods
Prior art date
Application number
MX2017008931A
Other languages
English (en)
Inventor
Baum Mark
Original Assignee
Imprimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imprimis Pharmaceuticals Inc filed Critical Imprimis Pharmaceuticals Inc
Publication of MX2017008931A publication Critical patent/MX2017008931A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Son descritas composiciones farmacéuticas y métodos para tratar varias enfermedades y patologías, como la contractura de Dupuytren, comprendiendo las composiciones pentoxifilina y un portador farmacéuticamente aceptable. También son descritos métodos para fabricar las composiciones y el uso de las mismas.
MX2017008931A 2015-01-06 2015-12-29 Formulaciones farmaceuticas de xantina o derivados de xantina. MX2017008931A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562100368P 2015-01-06 2015-01-06
PCT/US2015/067835 WO2016111885A1 (en) 2015-01-06 2015-12-29 Pharmaceutical formulations of xanthine or xanthine derivatives

Publications (1)

Publication Number Publication Date
MX2017008931A true MX2017008931A (es) 2017-10-19

Family

ID=56285898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008931A MX2017008931A (es) 2015-01-06 2015-12-29 Formulaciones farmaceuticas de xantina o derivados de xantina.

Country Status (8)

Country Link
US (1) US20160193213A1 (es)
EP (1) EP3242668A4 (es)
JP (1) JP2018505156A (es)
KR (1) KR20170096201A (es)
AU (3) AU2015375330A1 (es)
CA (1) CA2973087C (es)
MX (1) MX2017008931A (es)
WO (1) WO2016111885A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695351B2 (en) * 2018-07-30 2020-06-30 Harrow Ip, Llc Pharmaceutical formulations for the treatment of dry eye and methods for fabricating and using thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6998121B2 (en) * 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
AU2003286555A1 (en) * 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
AU2005210668A1 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
EP2219650B1 (en) * 2007-10-26 2014-05-07 Pacific Therapeutics Ltd. Compositions and methods for treating fibroproliferative disorders
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
EP2804606B1 (en) * 2012-01-19 2017-06-28 Hybrid Medical, LLC Topical therapeutic formulations

Also Published As

Publication number Publication date
JP2018505156A (ja) 2018-02-22
AU2015375330A2 (en) 2019-05-02
AU2015101954A4 (en) 2020-04-30
CA2973087C (en) 2021-07-13
KR20170096201A (ko) 2017-08-23
CA2973087A1 (en) 2016-07-14
EP3242668A1 (en) 2017-11-15
AU2015375330A1 (en) 2017-07-13
EP3242668A4 (en) 2018-09-19
US20160193213A1 (en) 2016-07-07
WO2016111885A1 (en) 2016-07-14
AU2019202127A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12016502552A1 (en) Formulation comprising a gemcitabine-prodrug
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2023006541A (es) Formulaciones de dosis fija.
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
IN2013MU03583A (es)
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018015363A (es) Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
TW201613861A (en) Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline